<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01526629</url>
  </required_header>
  <id_info>
    <org_study_id>1047</org_study_id>
    <nct_id>NCT01526629</nct_id>
  </id_info>
  <brief_title>Full Automaticity and Remote Follow-up</brief_title>
  <official_title>Identification of Implantable Cardioverter Defibrillator Patients With Remote Follow up That Requires an Onsite Visit</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Bakken Research Center</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medtronic Bakken Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      With the expansion of Sudden Cardiac Death (SCD) primary prevention indications, the number
      of Implantable Cardioverter Defibrillators (ICD) implants has increased significantly in the
      recent years. This has resulted in an increase of the number of follow-up (FU) to be
      performed and a growing workload for centers. Remote FU system such as the Medtronic Carelink
      system allows to check remotely the proper functioning of self evaluating devices and give
      informations of some clinical events.

      The objective of this study is to define which patients with a remote follow-up need
      additional onsite visit and to assess to which extent remote FU can be an alternative to
      onsite visit.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Remote Follow-up as an Alternative to Onsite Visit</measure>
    <time_frame>13 months</time_frame>
    <description>Evaluate the percentage of patients who had a successful remote follow up, as an alternative to onsite visit for patients implanted with a fully automatic ICD</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">354</enrollment>
  <condition>Tachyarrhythmia</condition>
  <arm_group>
    <arm_group_label>ICD patients with remote follow-up</arm_group_label>
    <description>Patients implanted with a fully automatic ICD and remotely followed-up.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patient implanted with a sigle- or dual-chamber ICD or a Cardiac
        Resynchronization-Defibrillator system (CRT-D) and remotely followed-up
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient older than 18,

          -  Patient implanted with a fully automatic ICD and remotely followed-up,

          -  Patient geographically stable and able to attend FU at investigative site

          -  Patient who signed a data release authorization form,

        Exclusion Criteria:

          -  Patient whose mental or physical capacity impedes to give an informed data release
             authorization,

          -  Patient already enrolled in a clinical study whose procedures may interfere with the
             results of the present study,

          -  Patients in New York Heart Association (NYHA) class IV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walid Amara, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier de Montfermeil</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CH Montfermeil</name>
      <address>
        <city>Montfermeil</city>
        <zip>93370</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2011</study_first_submitted>
  <study_first_submitted_qc>February 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2012</study_first_posted>
  <results_first_submitted>February 14, 2017</results_first_submitted>
  <results_first_submitted_qc>April 18, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 29, 2017</results_first_posted>
  <last_update_submitted>April 18, 2017</last_update_submitted>
  <last_update_submitted_qc>April 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ICD</keyword>
  <keyword>Remote follow-up</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ICD Patients With Remote Follow-up</title>
          <description>Patients implanted with a fully automatic ICD and remotely followed-up.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="354"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="308"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ICD Patients With Remote Follow-up</title>
          <description>Patients implanted with a fully automatic ICD and remotely followed-up.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="354"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Men</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" lower_limit="55" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Women</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" lower_limit="42" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="354"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Remote Follow-up as an Alternative to Onsite Visit</title>
        <description>Evaluate the percentage of patients who had a successful remote follow up, as an alternative to onsite visit for patients implanted with a fully automatic ICD</description>
        <time_frame>13 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ICD Patients With Remote Follow-up</title>
            <description>Patients implanted with a fully automatic ICD and remotely followed-up.</description>
          </group>
        </group_list>
        <measure>
          <title>Remote Follow-up as an Alternative to Onsite Visit</title>
          <description>Evaluate the percentage of patients who had a successful remote follow up, as an alternative to onsite visit for patients implanted with a fully automatic ICD</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="308"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>ICD Patients With Remote Follow-up</title>
          <description>Patients implanted with a fully automatic ICD and remotely followed-up.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="354"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Ventricular arrhytmias</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="354"/>
              </event>
              <event>
                <sub_title>Cardiac decompensation</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="354"/>
              </event>
              <event>
                <sub_title>Atrial arrhytmias</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="354"/>
              </event>
              <event>
                <sub_title>Event of aggravation</sub_title>
                <description>dyspnea, heart failure, stroke...</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="354"/>
              </event>
              <event>
                <sub_title>cardiovascular procedures</sub_title>
                <description>stent, ablation, transplantation..;</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="354"/>
              </event>
              <event>
                <sub_title>cardiovascular complication</sub_title>
                <description>aneurysm, pericarditis, stenosis...</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="354"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="354"/>
              </event>
              <event>
                <sub_title>Non cardiovascular causes</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="354"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Integrity default of material components</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="354"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Infection or pocket hematoma</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="354"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="354"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Latifa Foudali</name_or_title>
      <organization>Medtronic</organization>
      <phone>0155381700</phone>
      <email>latifa.foudali@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

